etrials Enters into Subscription Licensing Agreement with INC Research
11 October 2006
MORRISVILLE, NC and RALEIGH, NC - March 14, 2006 - etrials® Worldwide, Inc. (Nasdaq: ETWC, ETWCW, ETWCU), an eClinical software and services company focused on people, process and technology to meet the needs of the pharmaceutical industry, today announced that it has signed a subscription licensing agreement with INC Research, Inc®, a global, therapeutically specialized contract research organization (CRO). INC Research joins other leading companies enrolled in etrials’ CRO partnership program.
“At INC Research, we maintain a commitment to integrating innovative solutions into our processes in order to provide the highest quality service to our customers. eClinical technologies like electronic data capture, eDiaries and interactive voice response streamline our data collection, review and reporting processes. This enables our teams to focus on our customers, not the arduous task of integrating multiple data streams or managing disparate technologies,” said Anne Wiles, president of INC DataSpectrum, the data services division of INC Research.
“By recognizing the critical importance of offering fully integrated eClinical technologies, INC Research is able to offer their clients the best tools for their clinical research regardless of trial location, scope and complexity,” said John Cline, CEO of etrials. “INC Research fosters a deep commitment to satisfying customers through successful management of their critical programs.”
etrials’ subscription program provides its CRO partners with a significant competitive advantage by enabling them to offer clients cutting-edge technologies to significantly speed clinical trial research. As an etrials partner, CROs have access to etrials’ eClinical technologies for an annual subscription license fee, which enables effortless integration of all study data for faster and more efficient trials. etrials’ CRO partners offer their clients the technology needed to provide faster access to higher quality data, enabling them to bring important new drugs to market faster.
